Core Viewpoint - The company has approved a new compensation management system for its directors and senior management to enhance motivation and operational efficiency, pending shareholder approval [1][2]. Chapter Summaries Chapter 1: General Principles - The purpose of the new compensation management system is to establish an effective incentive and restraint mechanism for the company's directors and senior management, in accordance with relevant laws and regulations [1]. Chapter 2: Compensation Management Structure - The Compensation and Assessment Committee of the Board is responsible for formulating compensation plans and overseeing the performance evaluation of directors and senior management [2]. - The shareholders' meeting will review the compensation assessment system for directors, while the Board will review that for senior management [2]. Chapter 3: Compensation Standards and Payment Methods - Internal directors receive compensation based on their management roles, while external directors receive an annual allowance [3]. - Independent directors receive an annual allowance and are reimbursed for travel and other reasonable expenses incurred while performing their duties [4]. - Senior management compensation consists of a base salary, performance-based pay, and year-end bonuses, with specific criteria for each component [4][5]. - Compensation adjustments for directors and senior management will be based on industry salary trends, inflation, company performance, and other relevant factors [5]. Chapter 4: Supplementary Provisions - In case of conflicts between this system and existing laws or the company's articles of association, the latter will prevail [5]. - The system will take effect upon approval by the shareholders' meeting [5].

Core Viewpoint - The company has revised its external investment management system to enhance the management and supervision of its investment activities, aiming to control investment risks and improve returns for the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Principles - The purpose of the revised system is to strengthen the management of external investments, standardize investment behaviors, and protect the interests of the company and its shareholders [2]. - External investments are defined as activities where the company invests monetary funds, equity, and other assets to obtain future returns [2]. Chapter 2: Approval Authority and Organizational Management - The decision-making bodies for external investments include the shareholders' meeting, the board of directors, and the general manager's office, each with specific approval thresholds [5]. - Investments exceeding 50% of the latest audited total assets or 50% of audited annual revenue over 50 million yuan require board and shareholder approval [5][6]. Chapter 3: Implementation and Management of External Investments - The company must develop an implementation plan for external investments, detailing funding amounts, methods, and responsible personnel [6]. - The general manager is responsible for the overall planning and monitoring of investment projects, reporting progress to the board [6]. Chapter 4: Transfer and Recovery of External Investments - The transfer and recovery of external investments must be approved by the appropriate internal authorities [7]. - The company can recover investments under specific circumstances, such as project failure or bankruptcy [8]. Chapter 5: Supervision and Inspection - The audit department is tasked with establishing a supervision and inspection system for internal controls related to external investments [8]. - Any violations leading to investment losses will result in investigations and potential penalties for responsible parties [8]. Chapter 6: Supplementary Provisions - The revised system will take effect after approval by the shareholders' meeting and will be interpreted by the board of directors [11].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-070 北京诺思兰德生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.11： 《制定〈会计师事务所选 聘制度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总 则 第一条 为规范北京诺思兰德生物技术股份有限公司（以下简称"公司"）选 聘（含续聘、改聘）会计师事务所的行为，切实维护股东利益，提高财务信息质 量，根据《中华人民共和国公司法》 《中华人民共和国证券法》 《国有企业、上市 公司选聘会计师事务所管理办法》等有关法律、法规、规范性文件以及《北京诺 思兰德生物技术股份有限公司公司章程》 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-068 北京诺思兰德生物技术股份有限公司对外担保管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.09： 《修订〈对外担保管理制 度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总则 第一条 为规范北京诺思兰德生物技术股份有限公司（以下简称"公司"）对 外担保行为，控制和降低担保风险，保证股公司资产安全，根据《中华人民共和 国公司法》 《北京证券交易 《上市公司监管指引第 8 号——上市公司资金往来、对外担保 所股票上市规则》、 的监管要求》等法律法规、北京证券交易所业务规则以及《北京诺思兰德生物 ...

Core Viewpoint - The company has established a subsidiary management system to enhance governance and control over its subsidiaries, ensuring sustainable development and compliance with relevant laws and regulations [1][2]. Chapter Summaries Chapter 1: General Principles - The management system aims to strengthen the company's control over its subsidiaries and improve governance levels [1]. - The term "subsidiary" refers to companies that are included in the company's consolidated financial statements and are controlled by the company [2]. Chapter 2: Governance and Operations of Subsidiaries - Subsidiaries must adhere to the governance structure as per the Company Law and other relevant regulations [2]. - The operation of shareholders' meetings, boards of directors, and supervisory boards in subsidiaries must comply with legal and regulatory requirements [2]. - The company exercises shareholder rights through the subsidiary's shareholders' meeting, including the nomination and election of directors and supervisors [2]. Chapter 3: Management Principles for Subsidiaries - The system is designed to establish effective control mechanisms for the organization, resources, assets, investments, and operations of subsidiaries [3]. - The company is responsible for guiding, supervising, and providing services to its subsidiaries [3]. - Subsidiaries must report significant business and financial matters to the company in a timely manner [4]. Chapter 4: Management of Major Matters and Information Disclosure - Subsidiaries must report any external guarantee matters to the company before proceeding [4]. - Major external guarantees must follow the company's approval procedures [4]. - Subsidiaries are required to establish management systems for the use of raised funds and comply with the company's fundraising management regulations [4]. Chapter 5: Internal Audit Supervision - The company will conduct regular or irregular audits of its subsidiaries [5]. - Subsidiaries must cooperate with the audit process and prepare for audits as required [5]. Chapter 6: Supplementary Provisions - The management system will be executed in accordance with national laws and regulations, and the company's articles of association [6]. - The board of directors is responsible for the formulation and interpretation of this system [6]. - The system will take effect from the date of approval by the board of directors [6].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-073 北京诺思兰德生物技术股份有限公司累积投票实施细则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.14： 《北京证券交易所股票上市规则》等相关法律、法 规、规范性文件和《北京诺思兰德生物技术股份有限公司章程》 （以下简称"《公 司章程》"）的规定，制定本实施细则。 第二条 本实施细则所称累积投票制，是指公司股东会在选举董事时采用的 一种投票方式。即公司选举董事时，有表决权的每一股份拥有与应选董事人数相 同的表决权，股东拥有的表决权可以集中使用。 《制定〈累积投票实施细 则〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股 ...

Core Viewpoint - Replicate Bioscience has entered a long-term strategic partnership with Novo Nordisk to explore the potential applications of self-replicating RNA (srRNA) in infectious diseases, immunotherapy, and metabolic diseases, focusing on developing innovative drug candidates for obesity, type 2 diabetes, and related chronic conditions [2][3]. Group 1: Partnership Details - The collaboration will leverage Novo Nordisk's research and clinical expertise in cardiovascular metabolism alongside Replicate's unique srRNA platform to develop new therapies [2]. - Novo Nordisk will gain exclusive global rights to use Replicate's srRNA platform for project advancement and commercialization, while Replicate will receive upfront funding and may earn up to $550 million in total payments, including upfront cash and milestone rewards [2][3]. Group 2: Technology and Innovation - Replicate's srRNA technology allows for flexible protein expression patterns, enabling more efficient and sustained protein production compared to traditional RNA drugs, which require significant synthetic materials for adequate protein yield [3]. - The self-replicating nature of srRNA means that minimal synthetic material can achieve sufficient expression levels, presenting new possibilities for addressing complex diseases [3]. Group 3: Current Projects - Replicate is advancing key projects focused on srRNA drugs targeting IL-1 receptor agonists and IL-18 binding proteins, aiming to dual-block cytokine signaling pathways activated by inflammasomes, which are closely related to chronic inflammatory bowel disease, gout, and recurrent pericarditis [5].

Core Viewpoint - The article discusses the termination of a significant asset restructuring by Jia Bi You (688089), highlighting the company's strategic decision-making in response to changing market conditions and its ongoing business performance [2][4]. Group 1: Termination of Asset Restructuring - Jia Bi You announced the termination of its plan to acquire a 63.21% stake in Ou Yi Biological, which was initially valued at approximately 831 million yuan [4]. - The decision to withdraw the application for the asset purchase and related funding was made after thorough communication with relevant parties, and it does not impose any breach of contract liabilities on the company [4][5]. - The company emphasized that the termination of this transaction will not adversely affect its daily operations or the interests of its shareholders, particularly minority shareholders [4][5]. Group 2: Business Performance - In the first half of the year, Jia Bi You reported a revenue of 307 million yuan, representing a year-on-year growth of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a 59.01% increase [5]. - The demand for ARA and DHA products has been steadily increasing, driven by the gradual replacement of old national standard milk powder and the recovery of the maternal and infant consumption market due to birth subsidies [5]. - The concentration of leading milk powder brands in the industry has contributed significantly to the growth in sales of core customers [5].

北京英诺特生物技术股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励计划（草 案）的核查意见 北京英诺特生物技术股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会依据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法 则》"）、 律、法规及规范性文件和《北京英诺特生物技术股份有限公司章程》（以下简称 "《公司章程》"）的有关规定对公司《2025 年限制性股票激励计划（草案）》 （以 下简称"《激励计划（草案）》"）进行审核，发表核查意见如下： 情形，包括： （1）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （2）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； （3）上市后最近 36 个月内出现过未按法律法规、公司章程、公开承诺进行 利润分配的情形； （4）法律法规 ...

证券简称：英诺特 证券代码：688253 北京英诺特生物技术股份有限公司 （草案） 北京英诺特生物技术股份有限公司 二〇二五年八月 声明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励计划 所获得的全部利益返还公司。 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所科创板股票上市规则》《上市公司股权激励管理办法》《科创 板上市公司自律监管指南第 4 号——股权激励信息披露》等其他有关法律法规、 规范性文件，以及《北京英诺特生物技术股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）。股票 来源为北京英诺特生物技术股份有限公司（以下简称"公司"或"本公司"）从 二级市场回购或/和向激励对象定向发行公司 A 股普通股股票。 符合本激励计划授予 ...